A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index


About Ariad:

Ariad is a biopharmaceutical company engaged in developing novel therapies for aggressive and advanced-staged disease for which current treatments are inadequate. Their lead product candidate AP23573 is aimed to treat solid tumors and hematologic malignancies.

In parallel, they are moving ahead with the further development of their pipeline of preclinical programs:


Preclinical Programs -- oncogenic kinase inhibitor program, based on AP23464, to treat solid tumors and certain forms of leukemia and to block the spread of cancer, a major cause of morbidity and mortality in cancer; and their bone-targeted mTOR inhibitor program, based on AP23841, to treat cancer that has spread to bone and to treat primary bone cancers, such as osteogenic sarcomas.


Pipeline Chart and Product Development for Ariad



AP23573 Solid tumors and blood malignancies mTOR


More on Ariad

Home Page

Key Statistics fo ARIAD

Basic Chart for ARIAD

Analyst Opinion

Analysts Estimates

Biotech100 Index
What are the Requirements to be listed in the Biotech100 Index?
See the Biotech100 List

Sponsored Links

Clinical Trials
What is a Clinical Trial?
Phase I ,-- Phase II, -- PhaseIII
What is Randomized Control?
 What is a Double Blind Experiment?
What is the role of the FDA?


Key Biotech Terms


Biotech Resources


Investing in Stocks
Small Cap Stocks
Stocks and Bonds
Biotech100 Index

Careers and Employment
Biotechnology and Pharmaceutical
What are the Fastest Growing Careers?




Copyright 2005 BIOTECH100.COM. All rights reserved.